NCT02616224撤回不适用
A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Progression-Free Survival (PFS) For Each Anti-Cancer Treatment Regimen
研究概览
简要总结
This observational disease registry is a prospective, national, non-interventional study designed to enroll participants who have received an initial diagnosis of unresectable, locally advanced (LA) or metastatic breast cancer (mBC), up to 6 months prior to registry enrolment. These participants will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time
排除标准
- •There are no exclusion criteria for entry into this study.
结局指标
主要结局
Progression-Free Survival (PFS) For Each Anti-Cancer Treatment Regimen
时间窗: Up to approximately 8 years
次要结局
- Overall Survival (OS)(Up to approximately 8 years)
- Objective Response Rate (ORR) For Each Anti-Cancer Treatment Regimen(Up to approximately 8 years)
- Number and Percentage of Participants Receiving Each Unique Treatment Regimen Overall and as First-Line Therapy Versus Second-Line Therapy Versus Subsequent-Line Therapy(Up to approximately 8 years)
研究者
相似试验
进行中（未招募）
不适用
The REPLACE Registry for Cholbam® (Cholic Acid)Bile Acid Synthesis DisordersNCT03115086Mirum Pharmaceuticals, Inc.55
已完成
不适用
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast CancerLocally Advanced Breast CancerMetastatic Breast CancerNCT02595762Hoffmann-La Roche110
已完成
不适用
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry StudyBreast CancerNCT02393924Hoffmann-La Roche311
尚未招募
不适用
Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard TherapyHER2Advanced Gastric CancerAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Solid TumorNCT05649163Shen Lin306
已完成
不适用
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.Breast CancerNCT04498481Pfizer1